Document:

Document

EXHIBIT 10.11.1

February 28, 2019

Mr. Brent T. Novak
JAKKS Pacific, Inc.
2951 28th Street
Santa Monica, CA 90405

Dear Brent:

Reference is made to the Employment Agreement dated April 1, 2018 (the “Employment Agreement”) between JAKKS Pacific, Inc. (the “Company”) and Brent T. Novak (“Executive”).   This letter corrects Section 2(b)(ii) of the Employment Agreement.  The Company and Executive by his signature below confirm that in the first paragraph of Section 2(b)(ii), the reference to the “second and third anniversaries thereof” is corrected to refer to the “first and second anniversaries thereof”, and in Section 2(b)(ii)(B) the reference to “first anniversary of the Commencement Date” is corrected to refer to the “first anniversary of the grant date”. 

As corrected by this letter, the Employment Agreement remains in full force and effect.

Yours truly,

JAKKS Pacific, Inc.

By: ____________________________
Stephen Berman
President and CEO

CONFIRMED:

__________________________
Brent T. NovakExhibit 10.15

 

Director Compensation Arrangements

 

Compensation of Non-Employee Directors Upon Initial
Election to the Board

 

Each non-employee director will
be entitled to receive a non-qualified stock option having an aggregate Black-Scholes cash value of $134,400, rounded to the nearest
100 shares, provided that in no case shall such stock option be less than 25,000 shares (so long as 25,000 shares are required
to be granted under the equity incentive plan of the Corporation).  Such option shall be for the purchase of common stock
of the Corporation and shall vest annually over three years and be granted on the fifth business day following his or her initial
election to the Board.

 

 Annual Compensation of Non-Employee Directors

 

Annual Retainers

 

Each non-employee director will
be entitled to receive annual retainer amounts for each respective role on the Board. In lieu of cash, such aggregate annual retainer
amounts shall each be satisfied by the issuance of deferred stock awards of restricted stock units as described herein.

 

The respective annual retainer value
for each particular role on the Board are as follows:

 

	Role	 	Annual Retainer Value
	Non-employee director	 	$	35,280	 
	Chairman of the Board	 	$	35,280	 
	Audit Committee chair	 	$	18,144	 
	Audit Committee member	 	$	9,072	 
	Compensation Committee chair	 	$	12,096	 
	Compensation Committee member	 	$	6,048	 
	Governance Committee chair	 	$	5,040	 
	Governance Committee member	 	$	5,040	 

 

The annual retainer awards (each
a “Retainer Award”) are generally granted on the first trading day of January (the “Grant Date”) and vest
quarterly over the calendar year on each March 31, June 30, September 30 and December 31. The number of shares of common stock
subject to a Retainer Award is equal to the amount of cash that would have been received had the retainers all been paid in cash,
divided by the average daily closing market price of the common stock for the month of November immediately preceding the Grant
Date, rounded to the nearest 100 shares.

 

In the event that a non-employee
director is named Chairman or joins any committees of the Board of Directors during a fiscal year after the Grant Date, such director
shall be granted a Retainer Award (the “Additional Retainer Award”), in relation to such additional roles and respective
retainer amounts pro-rated for the remainder of such year. Such Additional Retainer Award shall be granted on the first trading
day of the month after the individual is appointed to such roles. The Additional Retainer Award shall vest in equal amounts spread
over the remaining quarterly vesting dates of the Retainer Awards for such calendar year subject to continued service as a non-employee
director on the applicable vesting dates. The number of shares of common stock subject to an Additional Retainer Award is equal
to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing
market price of the common stock for the calendar month that is two months prior to the month the director was appointed to the
additional roles, rounded to the nearest 100 shares (i.e., the month of June if the director was appointed to the additional roles
on August 15).

 

    

    

    

In the event a director’s
service (including as a Board member, or their role as Chairman, Committee Chairman, Committee member) ends during a particular
quarter, the vesting date for such quarter in relation to the portion of the award attributable to such roles that are ending,
shall be the last day of the director’s term in the respective role such that the full quarterly amount attributable to such
roles shall vest on that earlier vesting date.

 

Annual Equity Award

 

Each non-employee director will
also be entitled to receive an equity award having an aggregate cash value of $80,640, rounded to the nearest 100 shares, vesting
fully on the earlier to occur of (i) the date of the Corporation’s next Annual Meeting of Stockholders after the grant date,
immediately prior to the commencement of such meeting, and (ii) one year from the date of grant and granted on the fifth business
day following the Corporation’s Annual Meeting of Stockholders, with such award to be evidenced by a grant of deferred stock
awards of restricted stock units.  

 

Expenses

 

In addition, non-employee directors
shall be reimbursed for their expenses incurred in connection with attending Board and Committee meetings.EXHIBIT 10.50

 

SECOND AMENDMENT TO

HARVARD BIOSCIENCE, INC.

THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN

 

This Second Amendment to the Harvard Bioscience,
Inc. Third Amended and Restated 2000 Stock Option and Incentive Plan (the “Plan”) is effective as of May 28, 2015 (the
“Effective Date”).

 

Pursuant to the authorization and approval of
the Board of Directors and stockholders of Harvard Bioscience, Inc. in accordance with Section 17 of the Plan, the Plan is hereby
amended as follows, effective as of the Effective Date:

 

	 	1.	
        Section 3(a): The first sentence in Section 3(a) is hereby deleted
        in its entirety and replaced with the following in its stead:

         

        “a) Stock Issuable. Subject to
        adjustment as provided in Section 3(b), the maximum number of shares of Stock reserved and available for issuance under the Plan
        shall be 17,508,929 shares of Stock which number reflects the total of 3,750,000 shares originally reserved, plus the effect of
        an evergreen provision through December 31, 2005, plus an additional 2,000,000 shares added to the Plan in 2006, plus an additional
        2,500,000 shares added to the Plan in 2008 plus an additional 3,700,000 shares added to the Plan in 2011 plus an additional 1,941,254
        shares to account for the adjustment required by Section 3(b) pertaining to the Awards issued in connection with the spin-off of
        Harvard Apparatus Regenerative Technology, Inc. by Harvard Bioscience, Inc. plus an additional 2,500,000 shares added to the Plan
        in 2015.”

         

	
         

         
	2.	The following is added to the end of the Plan: 

 

“DATE SECOND AMENDMENT TO HARVARD BIOSCIENCE, INC.
THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN APPROVED BY BOARD OF DIRECTORS: APRIL 3, 2015.

 

DATE SECOND AMENDMENT TO HARVARD BIOSCIENCE, INC. THIRD
AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN APPROVED BY STOCKHOLDERS: MAY 28, 2015.”

 

	 	3.	Except as expressly amended hereby, the Plan shall remain in full force and effect. 

 

IN WITNESS WHEREOF, Harvard Bioscience, Inc. has
duly executed this amendment to be effective as the date first above written.

 

	 	 	 	 
	 	HARVARD BIOSCIENCE, INC.
	 	 	 
	 	By:	 	 /S/ Jeffrey A. Duchemin
	 	 	 	Name:  Jeffrey A. Duchemin 
	 	 	 	Title: Chief Executive OfficerEXHIBIT 10.51

AMENDMENT NO. 3 TO

HARVARD BIOSCIENCE, INC.

EMPLOYEE STOCK PURCHASE PLAN 

 

This Amendment No. 3 to the Harvard Bioscience,
Inc. Employee Stock Purchase Plan (the “Plan”) is effective as of May 18, 2017 (the “Effective Date”).

 

In accordance with Section 18 of the Plan, as
approved by the stockholders of Harvard Bioscience, Inc. on the Effective Date, in order to increase the number of shares of common
stock reserved for issuance under the Plan to One Million Fifty Thousand (1,050,000), the Plan is hereby amended as follows, effective
as of the Effective Date:

 

		1.	The reference to “Seven Hundred Fifty Thousand (750,000) shares” in the initial paragraph
of the Plan is hereby deleted and replaced with “One Million Fifty Thousand (1,050,000) shares”.

 

		2.	The following is added to the end of the Plan:

 

“DATE AMENDMENT NO. 1 TO PLAN APPROVED BY BOARD OF
DIRECTORS: AUGUST 2, 2011.

DATE AMENDMENT NO. 2 TO PLAN APPROVED BY BOARD OF DIRECTORS:
FEBRUARY 26, 2013.

DATE AMENDMENT NO. 2 TO PLAN APPROVED BY STOCKHOLDERS: MAY
23, 2013.

DATE AMENDMENT NO. 3 TO PLAN APPROVED BY BOARD OF DIRECTORS:
MARCH 31, 2017.

DATE AMENDMENT NO. 3 TO PLAN APPROVED BY STOCKHOLDERS: MAY
18, 2017.”

 

		3.	Except as expressly amended hereby, the Plan shall remain in full force and effect.

 

IN WITNESS WHEREOF, the Harvard Bioscience, Inc.
has duly executed this amendment to be effective as the date first above written.

 

	 	 	 	 
	 	HARVARD BIOSCIENCE, INC.
	 	 	 
	 	By:	 	 /s/ Robert E. Gagnon
	 	 	 	Name:  Robert E. Gagnon
	 	 	 	Title: Chief Financial OfficerEXHIBIT 10.52

 

THIRD AMENDMENT TO

HARVARD BIOSCIENCE, INC.

THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN

 

This Third Amendment to the Harvard Bioscience,
Inc. Third Amended and Restated 2000 Stock Option and Incentive Plan (the “Plan”) is effective as of May 17, 2018 (the
“Effective Date”).

 

Pursuant to the authorization and approval of
the Board of Directors and stockholders of Harvard Bioscience, Inc. in accordance with Section 17 of the Plan, the Plan is hereby
amended as follows, effective as of the Effective Date:

 

	 	1.	
        Section 3(a): The first sentence in Section 3(a) is hereby deleted
        in its entirety and replaced with the following in its stead:

         

        “a) Stock Issuable. Subject to
        adjustment as provided in Section 3(b), the maximum number of shares of Stock reserved and available for issuance under the Plan
        shall be 20,908,929 shares of Stock which number reflects the total of 3,750,000 shares originally reserved, plus the effect of
        an evergreen provision through December 31, 2005, plus an additional 2,000,000 shares added to the Plan in 2006, plus an additional
        2,500,000 shares added to the Plan in 2008, plus an additional 3,700,000 shares added to the Plan in 2011, plus an additional 1,941,254
        shares to account for the adjustment required by Section 3(b) pertaining to the Awards issued in connection with the spin-off of
        Harvard Apparatus Regenerative Technology, Inc. by Harvard Bioscience, Inc., plus an additional 2,500,000 shares added to the Plan
        in 2015, plus an additional 3,400,000 shares added to the Plan in 2018.”

         

	
         

         
	2.	The following is added to the end of the Plan: 

 

“DATE THIRD AMENDMENT TO HARVARD BIOSCIENCE, INC.
THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN APPROVED BY BOARD OF DIRECTORS: APRIL 2, 2018.

 

DATE THIRD AMENDMENT TO HARVARD BIOSCIENCE, INC. THIRD
AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN APPROVED BY STOCKHOLDERS: MAY 17, 2018.”

 

	 	3.	Except as expressly amended hereby, the Plan shall remain in full force and effect. 

 

IN WITNESS WHEREOF, Harvard Bioscience, Inc. has
duly executed this amendment to be effective as the date first above written.

 

	 	 	 	 
	 	HARVARD BIOSCIENCE, INC.
	 	 	 
	 	By:	 	 /s/ Jeffrey A. Duchemin
	 	 	 	Name:  Jeffrey A. Duchemin 
	 	 	 	Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]